OKUR
NASDAQOnKure Therapeutics Inc.
Price$4.20+0.01 (+0.24%)
02:00 PM07:15 PM
News · 26 weeks32-86%
2025-12-072026-05-31
Mix2590d
- SEC Filings10(40%)
- Insider9(36%)
- Other5(20%)
- Offering1(4%)
Latest news
25 items- SECSEC Form SCHEDULE 13G filed by OnKure Therapeutics Inc.SCHEDULE 13G - OnKure Therapeutics, Inc. (0001637715) (Subject)
- SECOnKure Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - OnKure Therapeutics, Inc. (0001637715) (Filer)
- SECSEC Form 10-Q filed by OnKure Therapeutics Inc.10-Q - OnKure Therapeutics, Inc. (0001637715) (Filer)
- PROnKure Therapeutics Reports First Quarter 2026 Financial Results-- Announced nomination of OKI-355, a next-generation PI3Kα pan-mutant selective inhibitor candidate, in vascular anomalies -- Initiated a discovery research program to expand the company's pipeline in vascular anomalies -- Announced nomination of OKI-345, a next generation PI3Kα pan-mutant selective inhibitor candidate, in breast cancer -- Closed $150 million private placement to advance next-generation PI3Kα pan-mutant programs into clinical development in 2027 -- $192 million cash and cash equivalents as of March 31, 2026, expected to fund operations into 2029 BOULDER, Colo., May 05, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ:OKUR), a clinical-stage biopharmaceutica
- SECSEC Form EFFECT filed by OnKure Therapeutics Inc.EFFECT - OnKure Therapeutics, Inc. (0001637715) (Filer)
- SECSEC Form S-3 filed by OnKure Therapeutics Inc.S-3 - OnKure Therapeutics, Inc. (0001637715) (Filer)
- SECSEC Form DEFA14A filed by OnKure Therapeutics Inc.DEFA14A - OnKure Therapeutics, Inc. (0001637715) (Filer)
- SECSEC Form DEF 14A filed by OnKure Therapeutics Inc.DEF 14A - OnKure Therapeutics, Inc. (0001637715) (Filer)
- INSIDERSEC Form 3 filed by new insider Ai Biotechnology Llc3 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- SECSEC Form SCHEDULE 13G filed by OnKure Therapeutics Inc.SCHEDULE 13G - OnKure Therapeutics, Inc. (0001637715) (Subject)
- SECSEC Form SCHEDULE 13G filed by OnKure Therapeutics Inc.SCHEDULE 13G - OnKure Therapeutics, Inc. (0001637715) (Subject)
- SECSEC Form SCHEDULE 13G filed by OnKure Therapeutics Inc.SCHEDULE 13G - OnKure Therapeutics, Inc. (0001637715) (Subject)
- INSIDERSEC Form 4 filed by Saccomano Nicholas A4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- INSIDERSEC Form 4 filed by Leverone Jason A.4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- INSIDERSEC Form 4 filed by Hartley Dylan4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- INSIDERSEC Form 4 filed by Agresta Samuel4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- INSIDERSEC Form 4 filed by Ratcliffe Liam4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- INSIDERSEC Form 3 filed by new insider Ratcliffe Liam3 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- SECOnKure Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities8-K - OnKure Therapeutics, Inc. (0001637715) (Filer)
- PROnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Kα Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular Anomalies-- Financing led by Access Biotechnology with participation from new and existing investors -- Financing to support advancement of two next-generation PI3Kα pan-mutant inhibitors for breast cancer and vascular anomalies – expect to file INDs for each program in 1H 2027 -- Liam Ratcliffe Joins OnKure's Board of Directors BOULDER, Colo., March 27, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ:OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines, today announced that it has entered into a securities purchase agreement for a private placement with certain institutional and accredited healthcare investors, raising gross proceeds of a
- INSIDERSEC Form 4 filed by Saccomano Nicholas A4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- INSIDERSEC Form 4 filed by Leverone Jason A.4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- SECSEC Form S-8 filed by OnKure Therapeutics Inc.S-8 - OnKure Therapeutics, Inc. (0001637715) (Filer)
- SECSEC Form 10-K filed by OnKure Therapeutics Inc.10-K - OnKure Therapeutics, Inc. (0001637715) (Filer)
- SECOnKure Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - OnKure Therapeutics, Inc. (0001637715) (Filer)
OKUR FAQ
6 questionsWhere does OKUR stock trade?
OnKure Therapeutics Inc. (OKUR) is listed on NASDAQ.What sector and industry is OKUR in?
OnKure Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did OnKure Therapeutics Inc. go public?
OnKure Therapeutics Inc. (OKUR) completed its IPO in 2021.What are analysts saying about OKUR?
OnKure Therapeutics Inc. has had 3 recent analyst actions on file. The most recent action was from Evercore ISI: Outperform on 2025-04-30. Recent price targets range from $3300.00 to $3500.00.What companies are similar to OKUR?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare OKUR side-by-side with any of them on Quantisnow.How can I track OKUR on Quantisnow?
Quantisnow aggregates OnKure Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow OKUR to receive live email and push alerts on every new disclosure.